Zydus receives final approval from the USFDA for Prochlorperazine Maleate Tablets

Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited) has received final approval from the United States Food and Drug Administration (USFDA) to market Prochlorperazine Maleate tablets, USP 5 mg and 10 mg, (USRLD: Compazine).

Prochlorperazine tablets are used to treat nervous, emotional, and mental conditions (eg. schizophrenia) and non-psychotic anxiety. It is also used to control severe nausea and vomiting. The drug will be manufactured at the group's formulation manufacturing facility at Ahmedabad SEZ, India.

Prochlorperazine Maleate tablets had annual sales of USD 30 million in the United States according to IQVIA MAT June 2022.

The group now has 320 approvals and has so far filed over 428* ANDAs since the commencement of the filing process in FY 2003-04.

Shares of Zydus Lifesciences Limited was last trading in BSE at Rs. 364.65 as compared to the previous close of Rs. 360.60. The total number of shares traded during the day was 55202 in over 1412 trades.

The stock hit an intraday high of Rs. 367.00 and intraday low of 358.05. The net turnover during the day was Rs. 20061686.00.

(*as of 30th June 2022)

Source : Equity Bulls

Keywords

ZydusLifesciences INE010B01027 FinalApproval USFDA ProchlorperazineMaleateTablets